New Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody – for Prevention or Treatment of H7N9 Influenza (Flu) A with Less Likelihood of Drug Resistance
H7N9 influenza viruses are predominately avian (bird) pathogens, however, since 2013, they have infected more than 1500 humans with a mortality rate of nearly 40% in confirmed cases. H7N9 viruses continue to be a threat to public health. Treatment for people infected with H7N9-subtype influenza A (H7N9) commonly includes the use of drugs that inhibit neuraminidase, a protein found on the virus’ surface. However, like other influenza viruses, H7N9 can become resistant to these drugs.